TRIDENT

Sanofi Licenses Seawolf DNA Delivery Programs

Seawolf disclosed a multi-target Sanofi research and exclusive-license collaboration covering bleeding disorders and other undisclosed indications. It cited up to $1.2 billion in research, development and commercial milestones plus tiered royalties. An upfront exists…